Thrombotic complications in patients with PMM2-CDG

M. Linssen, M. Mohamed, R. A. Wevers, D. J. Lefeber, Eva Morava-Kozicz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Many proteins regulating coagulation, including factor IX, factor XI, Antithrombin-III, Protein C and Protein S are deficient or decreased in activity in congenital disorders of glycosylation (CDG). Because of the imbalance of coagulation and anticoagulation factors, some patients develop acute vascular events, such as thrombosis. Identifying patients with increased risk for thrombotic events could prevent serious complications and even mortality. We performed a systematic review on patients diagnosed with the most common CDG form; PMM2-CDG, reported between 1990 and 2012 in medical literature. We also evaluated our PMM2-CDG patient-cohort of 15 patients. In total, based on the availability of comprehensive clinical descriptions, 100 patients were included in the study. Patients with and without thrombotic events were compared based on the alterations of the following glycosylated coagulation and anticoagulation factors: Antithrombin-III, Protein C, Protein S, factors IX and XI. We also assessed the global hemostasis, family history and provoking events. In the group of 100 PMM2-CDG patients 14 had suffered a venous or arterial thrombotic event. Low activity of several anticoagulation factors correlated with thrombotic events. Relatively high factor IX and XI activities were not associated with thrombosis. Prolonged PT and aPTT did not seem to protect against thrombosis in patients. Surgical procedures were frequently associated with thrombotic events. Based on the association of thrombosis and surgery in PMM2-CDG we advise to avoid elective surgical procedures in PMM2-CDG patients. Easily preventable risk factors like immobility should be treated with regular physiotherapy. We suggest a yearly follow-up for Antithrombin-III and Protein C levels and parent education for early thrombotic signs in CDG.

Original languageEnglish (US)
Pages (from-to)107-111
Number of pages5
JournalMolecular Genetics and Metabolism
Volume109
Issue number1
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Congenital Disorders of Glycosylation
Glycosylation
Factor XI
Factor IX
Antithrombin III
Antithrombin Proteins
Protein C
Coagulation
Thrombosis
Protein S
Blood Coagulation Factors
Physical therapy
Elective Surgical Procedures
Surgery
Hemostasis
Education
Association reactions
Availability
Blood Vessels

Keywords

  • AT-III
  • CDG
  • Coagulation factors
  • Glycosylation
  • Surgery
  • Thrombosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Thrombotic complications in patients with PMM2-CDG. / Linssen, M.; Mohamed, M.; Wevers, R. A.; Lefeber, D. J.; Morava-Kozicz, Eva.

In: Molecular Genetics and Metabolism, Vol. 109, No. 1, 01.05.2013, p. 107-111.

Research output: Contribution to journalArticle

Linssen, M. ; Mohamed, M. ; Wevers, R. A. ; Lefeber, D. J. ; Morava-Kozicz, Eva. / Thrombotic complications in patients with PMM2-CDG. In: Molecular Genetics and Metabolism. 2013 ; Vol. 109, No. 1. pp. 107-111.
@article{0c9591008ed14fefa3e9c3be7969fe66,
title = "Thrombotic complications in patients with PMM2-CDG",
abstract = "Many proteins regulating coagulation, including factor IX, factor XI, Antithrombin-III, Protein C and Protein S are deficient or decreased in activity in congenital disorders of glycosylation (CDG). Because of the imbalance of coagulation and anticoagulation factors, some patients develop acute vascular events, such as thrombosis. Identifying patients with increased risk for thrombotic events could prevent serious complications and even mortality. We performed a systematic review on patients diagnosed with the most common CDG form; PMM2-CDG, reported between 1990 and 2012 in medical literature. We also evaluated our PMM2-CDG patient-cohort of 15 patients. In total, based on the availability of comprehensive clinical descriptions, 100 patients were included in the study. Patients with and without thrombotic events were compared based on the alterations of the following glycosylated coagulation and anticoagulation factors: Antithrombin-III, Protein C, Protein S, factors IX and XI. We also assessed the global hemostasis, family history and provoking events. In the group of 100 PMM2-CDG patients 14 had suffered a venous or arterial thrombotic event. Low activity of several anticoagulation factors correlated with thrombotic events. Relatively high factor IX and XI activities were not associated with thrombosis. Prolonged PT and aPTT did not seem to protect against thrombosis in patients. Surgical procedures were frequently associated with thrombotic events. Based on the association of thrombosis and surgery in PMM2-CDG we advise to avoid elective surgical procedures in PMM2-CDG patients. Easily preventable risk factors like immobility should be treated with regular physiotherapy. We suggest a yearly follow-up for Antithrombin-III and Protein C levels and parent education for early thrombotic signs in CDG.",
keywords = "AT-III, CDG, Coagulation factors, Glycosylation, Surgery, Thrombosis",
author = "M. Linssen and M. Mohamed and Wevers, {R. A.} and Lefeber, {D. J.} and Eva Morava-Kozicz",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.ymgme.2013.02.006",
language = "English (US)",
volume = "109",
pages = "107--111",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Thrombotic complications in patients with PMM2-CDG

AU - Linssen, M.

AU - Mohamed, M.

AU - Wevers, R. A.

AU - Lefeber, D. J.

AU - Morava-Kozicz, Eva

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Many proteins regulating coagulation, including factor IX, factor XI, Antithrombin-III, Protein C and Protein S are deficient or decreased in activity in congenital disorders of glycosylation (CDG). Because of the imbalance of coagulation and anticoagulation factors, some patients develop acute vascular events, such as thrombosis. Identifying patients with increased risk for thrombotic events could prevent serious complications and even mortality. We performed a systematic review on patients diagnosed with the most common CDG form; PMM2-CDG, reported between 1990 and 2012 in medical literature. We also evaluated our PMM2-CDG patient-cohort of 15 patients. In total, based on the availability of comprehensive clinical descriptions, 100 patients were included in the study. Patients with and without thrombotic events were compared based on the alterations of the following glycosylated coagulation and anticoagulation factors: Antithrombin-III, Protein C, Protein S, factors IX and XI. We also assessed the global hemostasis, family history and provoking events. In the group of 100 PMM2-CDG patients 14 had suffered a venous or arterial thrombotic event. Low activity of several anticoagulation factors correlated with thrombotic events. Relatively high factor IX and XI activities were not associated with thrombosis. Prolonged PT and aPTT did not seem to protect against thrombosis in patients. Surgical procedures were frequently associated with thrombotic events. Based on the association of thrombosis and surgery in PMM2-CDG we advise to avoid elective surgical procedures in PMM2-CDG patients. Easily preventable risk factors like immobility should be treated with regular physiotherapy. We suggest a yearly follow-up for Antithrombin-III and Protein C levels and parent education for early thrombotic signs in CDG.

AB - Many proteins regulating coagulation, including factor IX, factor XI, Antithrombin-III, Protein C and Protein S are deficient or decreased in activity in congenital disorders of glycosylation (CDG). Because of the imbalance of coagulation and anticoagulation factors, some patients develop acute vascular events, such as thrombosis. Identifying patients with increased risk for thrombotic events could prevent serious complications and even mortality. We performed a systematic review on patients diagnosed with the most common CDG form; PMM2-CDG, reported between 1990 and 2012 in medical literature. We also evaluated our PMM2-CDG patient-cohort of 15 patients. In total, based on the availability of comprehensive clinical descriptions, 100 patients were included in the study. Patients with and without thrombotic events were compared based on the alterations of the following glycosylated coagulation and anticoagulation factors: Antithrombin-III, Protein C, Protein S, factors IX and XI. We also assessed the global hemostasis, family history and provoking events. In the group of 100 PMM2-CDG patients 14 had suffered a venous or arterial thrombotic event. Low activity of several anticoagulation factors correlated with thrombotic events. Relatively high factor IX and XI activities were not associated with thrombosis. Prolonged PT and aPTT did not seem to protect against thrombosis in patients. Surgical procedures were frequently associated with thrombotic events. Based on the association of thrombosis and surgery in PMM2-CDG we advise to avoid elective surgical procedures in PMM2-CDG patients. Easily preventable risk factors like immobility should be treated with regular physiotherapy. We suggest a yearly follow-up for Antithrombin-III and Protein C levels and parent education for early thrombotic signs in CDG.

KW - AT-III

KW - CDG

KW - Coagulation factors

KW - Glycosylation

KW - Surgery

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84876085700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876085700&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2013.02.006

DO - 10.1016/j.ymgme.2013.02.006

M3 - Article

C2 - 23499581

AN - SCOPUS:84876085700

VL - 109

SP - 107

EP - 111

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -